<DOC>
	<DOCNO>NCT01555619</DOCNO>
	<brief_summary>The purpose post approval study evaluate acute chronic performance Quadripolar CRT-D device system patient population indicate cardiac resynchronization therapy .</brief_summary>
	<brief_title>Quadripolar Pacing Post Approval Study</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Approved indication per current ACC/AHA/HRS guideline implantation CRTD system treatment heart failure life threaten ventricular tachyarrhythmia ( ) . 2 . Participated Promote® Q CRTD Quartet™ Left Ventricular Heart Lead Study ( IDE study ) , receive new Quadripolar CRTD device system implant undergo upgrade exist ICD pacemaker implant prior LV lead placement . 3 . Have ability provide inform consent study participation willing able comply prescribe followup test schedule evaluation 1 . Have hypersensitivity single 1.0mg dose dexamethasone sodium phosphate 2 . Have life expectancy le 5 year due condition 3 . Be less 18 year age</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Left heart pace lead</keyword>
	<keyword>Cardiac resynchronization therapy ( CRT )</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Quadripolar pacing</keyword>
</DOC>